Article information
Abstract
The antiphospolipid syndrome (APS) is an autoimmune disease characterized by recurrent fetal loss, thrombotic events (arterial or venous) and hemocytopenic disorders associated to high titers of circulating aPL. Two variants of the APS have been described. Primary APS is a clinical entity without evidence of any other autoimmune disease and secondary APS is a clinical disorder mainly associated with Systemic Lupus Erithematosus (SLE). aPL are a widely group of immunoglobulins directed against different components or proteins factors. In 1990 three groups of researchers identified that β2GP-I is the mainly antigenic target of aPL in APS patients. There are evidences that show that more than one pathogenic mechanism is involved in the development of the APS. The best documented clinical manifestations associated with the APS are recurrent fetal loss and thrombotic disorders. The latter is based on observations in vivo in animal models and in vitro on the effects caused by aβ2GP-I antibodies from patients with APS or from animals which cause experimental APS.
The objective of the present paper is to show the pathogenic mechanisms that participate in the development of the APS. We also presented evidence that shows that aβ2GP-I induces pro-inflammatory, pro-adhesive and pro-coagulant disorder.
Keywords:
Antiphospholipid syndrome
Antiphospholipid antibodies
Anti-β2Glycoprotein-I antibodies
Resumen
El síndrome de antifosfolípidos (SaF) es una enfermedad autoinmune caracterizada por abortos recurrentes, eventos trombóticos (arteriales o venosos) y hemocitopenias asociadas con títulos altos de aFL séricos. Se han descrito dos presentaciones de SaF: el SaF primario, que se presenta como entidad única y el SaF secundario o asociado principalmente a LEG.
Los aFL son un grupo heterogéneo de inmunoglobulinas dirigidas contra diversos componentes o factores proteicos. En 1990, tres grupos de investigadores identificaron a la β2GP-I como el principal blanco antigénico de los aFL presentes en los pacientes con SaF. Diversos trabajos han mostrado que existe más de un mecanismo patogénico involucrado en el desarrollo del SaF. Las manifestaciones clínicas mejor documentadas son los abortos recurrentes y las alteraciones trombóticas. Lo anterior se fundamenta en las evidencias observadas in vivo en modelos animales e in vitro causadas por los anticuerpos anti-β2GP-I (aβ2GP-I) de pacientes con SaF o de origen animal.
La presente revisión tiene como objetivo mostrar los mecanismos patogénicos que participan en el desarrollo del SaF. Presentamos, además, las evidencias que muestran que los aβ2GP-I inducen un estado proinflamatorio, proadhesivo y procoagulante.
Palabras clave:
Síndrome de antifosfolípidos
Anticuerpos antifosfolípidos
Anticuerpos anti-β2Glicoproteína-I
Full text is only aviable in PDF
References
[1.]
E.J. Bowie, J.H. Thompson, C.A. Pascuzzi, C.A. Owen.
Trombosis in systemic lupus erithematosus despite circulating anticoagulants.
J Lab Clin Med., 62 (1963), pp. 416-430
[2.]
E.N. Harris, A.E. Gharavi, M.L. Boey, B.M. Patel, C.G. Macworth-Young, S. Loizou, et al.
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.
Lancet., 2 (1983), pp. 1211-1214
[3.]
G.R.V. Hughes, E.N. Harris, A.E. Gharavi.
The anticardiolipin syndrome.
J Rheumatol., 13 (1986), pp. 486-489
[4.]
D. Alarcón-Segovia, M. Delezé, C.V. Oria, J. Sánchez-Guerrero, L. Gómez-Pacheco, J. Cabiedes, et al.
Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.
Medicine., 68 (1989), pp. 353-365
[5.]
D. Alarcón-Segovia, J. Sanchez-Guerrero.
Primary antiphospholipid syndrome.
J Rheumatol., 16 (1989), pp. 482-488
[6.]
C.G. Mackworth-Young, S. Loizou, M.J. Walport.
Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder.
Ann Rheum Dis., 48 (1989), pp. 362-367
[7.]
R.A. Asherson, M.A. Khamashta, J. Ordi-Ros, R.H.W.M. Derksen, S. Machin, J. Barquinero, et al.
The “primary” antiphospholipid syndrome: major clinical and serological features.
Medicine., 68 (1989), pp. 366-374
[8.]
P.H. McNeil, R.J. Simpson, C.N. Chesterman, S.A. Krilis.
Antiphospholipid antibodies are directed against complex antigen that include a lipid binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H).
Proc Natl Acad Sci USA., 87 (1990), pp. 4120-4124
[9.]
M. Galli, P. Comfurius, C. Maasen, H.C. Hemker, M.H. De Baets, P.J.C. Van Breda-Vriesman, et al.
Anticardiolipin antibodies directed not to cardiolipin but to plasma protein cofactor.
Lancet., 335 (1990), pp. 1544-1547
[10.]
E. Matsuura, Y. Igarashi, M. Fujimoto, K. Ichikawa, T. Koike.
Anticardiolipin cofactor(s) and differencial diagnosis of autoimmune disease (letter).
Lancet., 336 (1990), pp. 177-178
[11.]
D. Alarcón-Segovia, A.R. Cabral.
The anti-phospholipid antibody syndrome: clinical and serological aspects.
Baillières Clin Rheumatol., 14 (2000), pp. 139-150
[12.]
S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, S.R.L. Brey, R. Cervera, et al.
International Consensus statement on an update of the classification criteria for definite APS.
J Thromb Haemost., 4 (2006), pp. 295-306
[13.]
J. Cabiedes, A.R. Cabral, D. Alarcón-Segovia.
Clinical manifestations of the antiphospholipid síndrome in systemic lupus erythematosus patients associate more strongly with anti-b2-glycoprotein I than with antiphospholipid antibodies.
J Rheumatol., 22 (1995), pp. 1899-1906
[14.]
E.I. Gómez Suarez, J. Cabiedes.
Estandarización de un inmunoensayo de captura para la determinación de los niveles séricos de b2GP-I en sujetos sanos y en pacientes con SaF primario y asociado a LEG.
Tesis de Licenciatura,
[15.]
D. Alarcón-Segovia.
Pathogenic potential of anti-phospholipid antibodies.
J Rheumatol., 15 (1988), pp. 890-893
[16.]
G. Espinoza, R. Cervera, J. Font, Y. Shoenfeld.
Anthiphospholipid syndrome: pathogenic mechanism.
Autoinmmun Rev., 2 (2003), pp. 86-93
[17.]
V. Pengo, A. Biasiolo, T. Brocco, S. Tonetto, A. Ruffatti.
Autoantibodies to phospholipidbinding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies.
Thromb Haemost., 75 (1996), pp. 721-724
[18.]
J.D. Oosting, K.T. Preissner, R.H.W.M. Derksen, P.G. De Groot.
Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro.
Br J Haematol., 85 (1993), pp. 761-768
[19.]
T. Mori, H. Takeya, H. Nishioka, E.C. Gabazza, K. Suzuki.
b2-glycoprotein I modulates the anticoagulant activity of protein C on the phospholipid surface.
Thromb Haemost., 75 (1996), pp. 49-55
[20.]
P.M. Cosgriff, B.A. Martin.
Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis.
Arthritis Rheum., 24 (1981), pp. 94-96
[21.]
G. Lakos, E. Kiss, N. Regeczy, P. Tarjan, P. Soltesz, M. Zeher, et al.
Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases.
J Rheumatol., 27 (2000), pp. 924-929
[22.]
E. Pasquier, J. Amiral, M.L. De Saint, D. Mottier.
A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism.
Thromb Haemost., 86 (2001), pp. 538-542
[23.]
J. Nojima, H. Kuratsune, E. Suehisa, Y. Futsukaichi, H. Yamanishi, T. Machii, et al.
Association between the prevalence of antibodies to beta(2)-glycoprotein I, trothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications.
Clin Chem., 47 (2001), pp. 1008-1015
[24.]
J.C. Reverter, D. Tàssies, J. Font, J. Monteagudo, G. Escolar, M. Ingelmo, et al.
Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S.
Arterioscler Thromb Vasc Biol., 16 (1996), pp. 1319-1326
[25.]
J.C. Reverter, D. Tàssies, J. Font, M.A. Khamashta, K. Ichikawa, R. Cervera, et al.
Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.
Arthritis Rheum., 41 (1998), pp. 1420-1427
[26.]
P.M. Dobado-Barrios, C. Lopez-Pedrera, F. Velasco, M.A. Aguirre, A. Torres, M.J. Cuadrado.
Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome.
Thromb Haemost., 82 (1999), pp. 1578-1582
[27.]
J.D. Oosting, R.H.W.M. Derksen, L. Blokzijl, J.J. Sixma, P.G. De Groot.
Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity: studies in a thrombosis model.
Thromb Haemost., 68 (1992), pp. 278-284
[28.]
D.W. Branch, G.M. Rodgers.
Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis.
Am J Obstet Gynecol., 168 (1993), pp. 206-210
[29.]
P.L. Meroni, E. Raschi, M. Camera, C. Testoni, F. Nicoletti, A. Tincani, et al.
Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome.
J Autoimmun., 15 (2000), pp. 237-240
[30.]
S.S. Pierangeli, M. Colden-Stanfield, X. Liu, J.H. Barker, G.L. Anderson, E.N. Harris.
Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.
Circulation., 99 (1999), pp. 1997-2002
[31.]
J.E. Salmon, G. Girardi, M. Holers.
Complement activation as a mediator of antiphospholipid antibodies induced pregnancy loss and thrombosis.
Ann Rheum Dis., 61 (2002), pp. 46
[32.]
S.S. Pierangeli, R.G. Espinola, X. Liu, E.N. Harris.
Thrombogenic effects of antiphospholipids antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1 and P-selectin.
Circ Res., 88 (2001), pp. 245-250
[33.]
G. Girardi, J. Berman, P. Redecha, L. Spruce, J.M. Thruman, D. Kraus, et al.
Complement C5a receptors and neutrophils mediate fetal injury in the Antiphospholipid syndrome.
J Clin Invest., 112 (2003), pp. 1644-1654
[34.]
S.S. Pierangeli, G. Girardi, M. Vega-Ostertag, X. Liu, R.G. Espinola, J.E. Salmon.
Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.
Arthritis Rheum., 52 (2005), pp. 2120-2124
[35.]
N. Di Simone, E. Raschi, C. Testoni, R. Castellani, M. D’Asta, T. Shi, et al.
Pathogenic role of anti-beta 2 glycoprotein I antibodies in antiphospholipid associated fetal loss: characterization of beta 2 glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2 glycoprotein I antibodies in vitro.
Ann Rheum Dis., 64 (2005), pp. 462-467
[36.]
W. Shi, B.H. Chong, C.N. Chesterman.
beta-2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants.
Blood., 81 (1993), pp. 1255-1262
[37.]
M. Blank, I. Krause, N. Lanir, P. Vardi, B. Gilburd, A. Tincani, et al.
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation: the importance of the T cell.
Arthritis Rheum., 38 (1995), pp. 115-122
[38.]
M. Kuwana.
Autoreactive CD4+ T cells to beta-2 glycoprotein-I in patients with antiphospholipid syndrome.
Autoimmun Rev., 2 (2003), pp. 192-198
[39.]
C.A. Núñez-Álvarez, A. Ortega, D.F. Hernández-Ramírez, V. Pascual-Ramos, A. Martínez Castillo, C. Cabral, et al.
Proliferación de células mononucleares de sangre periférica (CMNSP) de una paciente con SaFP inducida por b2GP-I de fenotipo valina o leucina (V/L)247.
Reumatol Clin., 4 (2008), pp. 30
[40.]
T. Arai, K. Yoshida, J. Kaburaki, H. Inoko, Y. Ikeda, Y. Kawakami, et al.
Autoreactive CD4+ T-cell clones to beta-glycoprotein I in patients with APS: preferential recognition of the major phospholipid-binding site.
Blood., 98 (2001), pp. 1889-1896
[41.]
H. Ito, S. Matsushita, Y. Tokano, H. Nishimura, Y. Takana, S. Fujisao, et al.
Analysis of T cell responses to the beta2-glycoprotein I-derived peptide library in patients with anti-beta2-glycoprotein I antibody associated autoimmunity.
Hum Immunol., 61 (2000), pp. 366-377
[42.]
G.A. Prieto, A.R. Cabral, M. Zapata-Zuniga, A.J. Simon, A.R. Villa, D. Alarcón-Segovia, et al.
Valine/valine genotype at position 247 of the b2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-b2-glycoprotein I antibodies.
Arthritis Rheum., 48 (2003), pp. 471-474
[43.]
C.A. Núñez-Álvarez, D.F. Hernández-Ramírez, B. Calderón, A.R. Cabral, J. Cabiedes.
Caracterización de clonas de linfocitos B obtenidos de una paciente con SaF Primario.
Reumatol Clin., 5 (2009), pp. 55
[44.]
T.R. Mosmann, H. Cherwinski, M.W. Bond, M.A. Giedlin, R.L. Coffman.
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986.
J Immunol., 175 (2005), pp. 5-14
[45.]
W. Ouyang, J.K. Kolls, Y. Zheng.
The biological functions of T helper 17 cell effector cytokines in inflammation.
Immunity., 28 (2008), pp. 454-467
[46.]
I. Krause, M. Blank, Y. Levi, T. Koike, V. Barak, Y. Shoenfeld.
Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.
Clin Exp Immunol., 117 (1999), pp. 190-197
[47.]
S. Visvanathan, P. McNeil.
Cellular Immunity to beta2-Glycoprotein-1 in patients with the Antiphospholipid Syndrome.
J Immunol., 162 (1999), pp. 6919-6925
[48.]
M. Karakantza, G.L. Theodorou, N. Meimaris, A. Mouzaki, E. John, A.P. Andonopoulos, et al.
Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome.
Ann Hematol., 83 (2004), pp. 704-711
[49.]
J. Berman, G. Girardi, J.E. Salmon.
TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.
J Immunol., 174 (2005), pp. 485-490
[50.]
C. Hamid, K. Norgate, D.P.D. Cruz, M.A. Kamashta, M. Arno, J.D. Pearson, et al.
Anti b2GP-I antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.
Ann Rheum Dis., 66 (2007), pp. 1000-1007
[51.]
S. Stone, R. Pijnenborg, L. Vercruysse, R. Poston, M.A. Khamashta, B.J. Hunt, et al.
The placental bed in pregnancies complicated by primary antiphospholipid syndrome.
Placenta., 27 (2006), pp. 457-467
Recommended
articles
articles
Reumatol Clin. 2020;16P2:133-48
Reumatol Clin. 2024;20:155-61
Reumatol Clin. 2023;19:197-203
Publish in
Reumatología Clínica
Free access articles
10.1016/j.reumae.2024.11.004
Reumatol Clin. 2024;20:440-51
Reumatol Clin. 2024;20:416-22